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ETV6-RUNX1 is associated with childhood acute
B-lymphoblastic leukemia (cALL) functioning as a
first-hit mutation that initiates a clinically silent pre-
leukemia in utero. Because lineage commitment hier-
archies differ between embryo and adult, and the
impact of oncogenes is cell-context dependent, we
hypothesized that the childhood affiliation of ETV6-
RUNX1 cALL reflects its origins in a progenitor
unique to embryonic life. We characterize the
first emerging B cells in first-trimester human em-
bryos, identifying a developmentally restricted
CD19IL-7R+ progenitor compartment, which transi-
tions from a myeloid to lymphoid program during
ontogeny. This developmental series is recapitulated
in differentiating human pluripotent stem cells
(hPSCs), thereby providing a model for the initiation
of cALL. Genome-engineered hPSCs expressing
ETV6-RUNX1 from the endogenous ETV6 locus
show expansion of the CD19IL-7R+ compartment,
show a partial block in B lineage commitment,
and produce proB cells with aberrant myeloid
gene expression signatures and potential: features
(collectively) consistent with a pre-leukemic state.
INTRODUCTION
Childhood acute lymphoblastic leukemia (cALL) is clinically
distinct from that in adults, with higher incidence, better prog-Developmental Cell 44, 1–16, F
This is an open access article undnosis, and a distinct mutational spectrum. Analysis of neonatal
blood spots andmonochorionic twins of ALL cases have demon-
strated that the initiating mutations are frequently acquired in
utero (Greaves and Wiemels, 2003). One possibility for this is
that fetal B lineage progenitors have a developmental suscepti-
bility to pre-leukemic initiation. We therefore hypothesized that
the distinct features of childhood ALL are due in part to its initia-
tion in a transient progenitor compartment with B lineage poten-
tial unique to early human development.
ETV6-RUNX1 (TEL-AML1) accounts for 25% of precursor
B cell ALL (B-ALL) in children, but is seldom seen in adult ALL.
Evidence from both neonatal blood spots and monochor-
ionic twins of ETV6-RUNX1 ALL cases, supported by deep
sequencing, has demonstrated that ETV6-RUNX1 frequently
arises in utero, is unequivocally an initiating event (Greaves,
2003; Papaemmanuil et al., 2014), and occurs at high frequency,
with approximately 1% of neonates harboring this first-hit trans-
location (Mori et al., 2002). However, only 1% of children with the
ETV6-RUNX1 mutation develop the necessary second-hit muta-
tions to transform to overt ALL, indicating that this is a common,
but weakly penetrant first-hit oncogene. These secondary muta-
tions are acquired in a branching polytypic evolutionary pattern
(Anderson et al., 2011), although the exact mechanisms underly-
ing transformation to ALL remain uncertain. Deep-sequencing
studies have shown most second-hit mutations have evidence
of recombination activating gene (RAG)-mediated mutagenesis,
while other studies have implicated activation-induced cyti-
dine deaminase-mediated mutagenesis, exposure to infective
agents, and aberrant response of B cell precursors to cyto-
kine signaling (Ford et al., 2009; Greaves, 2006; Papaemmanuil
et al., 2014; Swaminathan et al., 2015).
Understanding the natural history of pre-leukemic initiation
and subsequent transformation requires knowledge of both theebruary 5, 2018 ª 2017 The Author(s). Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Please cite this article in press as: Bo¨iers et al., A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction as Developmental Susceptibility
to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1, Developmental Cell (2017), https://doi.org/10.1016/j.devcel.2017.12.005cell in which the first-hit mutation arises, but most pertinently the
downstream compartments that are impacted. Single-cell IGH
and TCR sequencing of monochorionic twins with ETV6-
RUNX1 childhood ALL have been particularly informative, iden-
tifying common ancestral clones containing partial IGHDJ or
even TCR rearrangements (Alpar et al., 2015). This strongly indi-
cates that leukemic transformation occurs within an early RAG-
expressing multipotent lymphoid progenitor, which has either
been trapped by differentiation arrest and/or expanded by
ETV6-RUNX1. In addition, the failure to identify polyclonal IgH
DJ or TCR rearrangements in ETV6-RUNX1 pre-leukemia make
it unlikely that the ETV6-RUNX1 pre-leukemic hierarchy is main-
tained by a more primitive RAG– hematopoietic stem cell (HSC)-
like population (Alpar et al., 2015; Hong et al., 2008). This
notwithstanding, the clinical features of aberrant co-expression
of myeloid antigens and lineage switching commonly seen in
many childhood B-ALLs indicate that the disease may arise in
a target progenitor cell that normally harbors some degree
of myeloid as well as lymphoid lineage programming (Gerr
et al., 2010).
Detailed studies of mouse embryonic hematopoiesis have
characterized developmental differences with multiple sites of
specification, niches, and the production of functionally distinct
effector cells (Medvinsky et al., 2011; Yuan et al., 2012). Blood,
mainly erythrocytes and macrophages, first arises in the yolk
sac (Tavian and Peault, 2005), whereas the first definitive
HSCs (dHSCs) are formed in the aorta gonad mesonephros
(AGM) region in both mouse (at embryonic day 10.5) and human
(around 30 days post fertilization) (Ivanovs et al., 2011; Medvin-
sky and Dzierzak, 1996). HSCs and progenitors migrate from the
AGM to the fetal liver (FL), which becomes themain site of hema-
topoiesis before the bone marrow (BM) takes over just before
birth (Tavian and Peault, 2005).
Development of the adaptive immune system (B and T cells)
was believed to occur after the emergence of dHSCs at the
AGM; however, a recent study detected murine fetal inter-
leukin-7 receptor (IL-7R+) Rag1-expressing lymphoid progenitor
much earlier (Boiers et al., 2013). This early immune-restricted
progenitor co-expressed myeloid and lymphoid lineage pro-
grams and contributed to both myeloid and lymphoid lineages
in the embryo, whereas in the adult Rag-1 progenitors contrib-
uted almost exclusively to the lymphoid lineage. This murine
study indicates important differences in the lineage specification
of fetal and adult B cell progenitors, which, if found in the human,
might underlie a developmental susceptibility to pre-leukemic
initiation by fusion transcription factors such as ETV6-RUNX1.
There have been several attempts to model pre-leukemic initi-
ation by ETV6-RUNX1 in mouse and human. These have pro-
duced variable results as to the molecular mechanism of
ETV6-RUNX1 and have implicated a target cell anywhere from
HSC to B lineage-restricted cells (Hong et al., 2008; Schindler
et al., 2009; van der Weyden et al., 2011). Furthermore, ETV6-
RUNX1 expression level has been shown to affect the observed
phenotype, raising concerns over the veracity of models using
viral transgenesis (Tsuzuki and Seto, 2013). Of note, authentic
B lineage ALL in response to ETV6-RUNX1, with or without the
second hits found in ETV6-RUNX1 patients, has not been reliably
seen in non-humanmodel systems (van derWeyden et al., 2011).
Together this implies that ETV6-RUNX1 exerts a relatively subtle2 Developmental Cell 44, 1–16, February 5, 2018first-hit activity, and that any model of the pre-leukemic effect of
ETV6-RUNX1 requires a developmentally relevant human sys-
tem expressing physiological levels of ETV6-RUNX1.
We hypothesized that the distinct features of childhood ALL
are due in part to its initiation in a transient progenitor compart-
ment with B lineage potential unique to early human develop-
ment. Thus, to establish the authentic first-hit impact of the
cALL oncogene ETV6-RUNX1 necessitates its expression in
the transcriptional context of the appropriate developmental
stage. Studies of both mouse and human embryonic hemato-
poiesis have demonstrated unique progenitor states during
development (Boiers et al., 2013; Notta et al., 2015), and it is
increasingly understood that oncogenic mutations can have
distinct effects on cell fate in different developmental contexts
(Horton et al., 2013; Man et al., 2016; Porter et al., 2016). Under-
standing the interaction of leukemia-initiating mutations with
developmentally restricted cell states requires a model of the
relevant stages of human fetal B lymphopoiesis. While this is
almost impossible using primary material from human fetuses,
in vitro differentiation of human pluripotent stem cells (hPSCs)
potentially offers a tractable system to model early embryonic
hematopoiesis (Slukvin, 2013), although it remains unclear which
developmental hematopoietic hierarchy it recapitulates. hPSCs
are known to produce cells expressing embryonic hemoglobins,
and attempts to produce transplantable dHSCs from hPSCs
have been inconsistent (Slukvin, 2013). If hPSC-derived B cell
precursors recapitulate important developmental characteristics
of the earliest B lymphoid progenitor cells in the human embryo,
then hPSCs could provide a tractable model to explore the
impact of cALL oncogenes on this currently inaccessible arena
of human development.
We have characterized B lymphoid development in first-
trimester human embryos, identifying an IL-7R+ progenitor
compartment that transitions from myeloid to lymphoid pro-
gramming during development, resulting in a transient popula-
tion that co-expresses myeloid and B lymphoid genes. We
demonstrate that hPSCs recapitulate this fetally distinct B cell
progenitor hierarchy, providing a developmentally relevant
model of early embryonic B lymphopoiesis. ETV6-RUNX1 ex-
pressed at physiological levels from the ETV6 promoter in
genome-engineered hPSCs specifically affects the transition
from fetal IL-7R+ progenitor compartment to committed proB
cell. We therefore propose that the lineage dynamics of the fetal
IL-7R+ compartment are particularly susceptible to dysregula-
tion by ETV6-RUNX1, thereby providing an explanation for the
childhood restriction of cALL.
RESULTS
The Majority of Emerging B Cells in the Human FL
Express IL-7R
We examined first-trimester human FL aiming to identify the
earliest emerging CD19+ B cells and compare them with
neonatal cord blood (CB) and adult BM B cells (schematic over-
view of ontogeny; Figure 1A). At Carnegie stage (CS) 17we found
a small population of CD19+ B cells in three out of four FL sam-
ples (<0.5% of total CD45+ blood cells). These CD19+ B cells co-
expressed the progenitor marker CD34, consistent with the proB
stage of development (Figures 1B and 1C, top panel) (Hystad
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Figure 1. The Majority of Emerging B Cells in the Human Fetal Liver Express IL-7R
(A) Major hematopoietic sites in the developing human embryo. Timescale shows days of gestation and embryonic development by Carnegie stage (CS) (Tavian
and Peault, 2005).
(B) CD19+ B cells from human fetal livers (FLs) at CS17 and CS21-22, cord blood (CB) and adult bonemarrow (BM) were analyzed for surface expression of IL-7R.
Viable cells were gated CD45+LIN, further gating as indicated. Top panel: mean percentage CD19+ B cells of total CD45+ cells. Bottom panel: mean percentage
of CD19+ B cells expressing IL-7R.
(C) Emergence of CD19+ B cells as percent of total CD45+ cells (top panel) and percent CD19+ B cells expressing IL-7R (bottom panel) at different time points of
development. Each dot represents one biological sample. Mean with range.
(D) Quantitative gene-expression analysis of CD34+CD19+ proB cells (CS 20–21 FL and CB). Data are presented relative to GAPDH; mean ± SD, n = 2–3.
See also Figure S1.
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to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1, Developmental Cell (2017), https://doi.org/10.1016/j.devcel.2017.12.005et al., 2007). By CS20 we saw the emergence of more mature
CD34CD19+ preB cells (Figures 1B, 1C, and S1A). We looked
for surface markers that could discriminate between fetal and
adult B cells. The majority of FL CD19+ B cells expressed
IL-7R, with as many as 60%–88% FL CD19+ B cells being
IL-7R+, whereas in adult BM amuch smaller fraction were IL-7R+(9.8% total CD19+ and 19% proB) (Figures 1B and 1C, bottom
panel, and S1B). This was confirmed by qPCR (Figure 1D, sorting
profiles Figure S1A). Expression of the tyrosine kinase receptor
KIT, also implicated in regulation of B lymphopoiesis (Waskow
et al., 2002), was higher in the FL proB cells, which we confirmed
by flow cytometry (data not shown), whereas DNTT (encodingDevelopmental Cell 44, 1–16, February 5, 2018 3
Please cite this article in press as: Bo¨iers et al., A Human IPS Model Implicates Embryonic B-Myeloid Fate Restriction as Developmental Susceptibility
to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1, Developmental Cell (2017), https://doi.org/10.1016/j.devcel.2017.12.005TDT) was higher in neonatal CB proB cells, consistent with
studies in mice (Li et al., 1993). Embryonic hematopoietic tissues
are known to express LIN28B and we found it to be upregulated
in FL proB cells compared with CB (Yuan et al., 2012).
Identification of a CD19–IL-7R+ Progenitor
We next looked for a candidate upstream progenitor of the fetal
proB cells identified above. As surface expression of IL-7R
was so prominent in emerging proB cells, we hypothesized
that they may arise from a more primitive CD19–IL-7R+ progen-
itor. We explored hematopoietic progenitor compartments
(CD45+CD34+), excluding cells expressing lineage commitment
markers (LIN: CD19, CD3, CD8a, CD56, and CD235a), and iden-
tified a candidate LINIL-7R+ population in the early FL. In com-
mon with fetal proB cells the IL-7R+ population also expressed
KIT (CD117), CD45RA, and the activation marker CD38 (Figures
2A, S2A, and S2B). The frequency of cells with this immunophe-
notype as a proportion of the CD45+CD34+ progenitor compart-
ment decreased markedly through development with a 7- to
10-fold difference between CS17 FL and CB or adult BM
(Figure 2B).
We tested the capacity of the IL-7R+ population to form B cells
by co-culture on MS-5 stroma. The FL CD19–IL-7R+ cells
(LINCD19CD34+CD38+CD45RA+IL-7R+KIT+) efficiently pro-
duced CD19+ B cells (Figure 2C, sort profiles Figure S2A)
demonstrating that this population is indeed a B cell progenitor
(henceforth referred to as the IL-7R progenitor). That the IL-7R
progenitor robustly formed B cells in vitro prompted us to inves-
tigate if the progenitor had initiated rearrangement of the immu-
noglobulin heavy chain (van Dongen et al., 2003). We found that
the IL-7R progenitor had evidence of DJH rearrangement (Fig-
ure 2D), although, as expected, fewer cells appeared DJ rear-
ranged than in the proB cell population.
The fetal IL-7R progenitor compartment was also capable of
producing myeloid output of predominantly macrophage lineage
in both semi-solid and liquid culture, with a frequency equivalent
to that from a CD34+ primitive control fraction (Figures 2E and
2F). No detectable erythroid potential was seen in semi-solid cul-
ture, indicating that the IL-7R progenitor is immune restricted
(Figure 2E).
The IL-7R Progenitor Transitions from a Myeloid to a
Lymphoid Gene Expression Signature during Early
Embryonic Development
Consistent with the lymphoid and myelomonocytic outputs seen
from this population in vitro, we observed evidence of both
myeloid- and lymphoid-affiliated gene expression by qPCR anal-
ysis of bulk IL-7R progenitor cells (data not shown). To under-
stand whether these programs were co-expressed within single
cells, we performed single-cell expression analysis of lineage-
associated genes at different stages of development (Figure 3A).
As expected, the FL IL-7R progenitor expressed the fetal
marker LIN28B, which was not seen in adult BM; conversely,
the adult BM IL-7R progenitor expressed DNTT, which was
not seen in the FL (Li et al., 1993; Yuan et al., 2012). Overall,
the earliest IL-7R progenitor cells fromCS17 expressed predom-
inantly myeloid genes, with the majority of cells lacking an
identifiable or coherent lymphoid program. By CS20, early
lymphoid- and B cell-specific programs were expressed while4 Developmental Cell 44, 1–16, February 5, 2018retaining a myeloid signature, suggesting that the IL-7R progen-
itor had transitioned from a myeloid-primed to a lympho-
myeloid-primed transcriptional state (Figure 3A). Consistent
with the identification of DJ rearrangements in the IgH gene
from the FL IL-7R progenitor (Figure 2D), RAG2 is expressed in
almost all of the IL-7R+ progenitor cells we tested from this
stage of development. Collectively, these transcriptional data
are consistent with the functional data showing myeloid and
lymphoid output from the FL IL-7R progenitor at the population
level (Figures 2C, 2E, and 2F). To confirm that any given cell
within this population truly had dual lympho-myeloid potential,
we assessed IGH DJ status within myeloid cells derived from
this population. The presence of DJ rearrangements within these
myeloid cells demonstrates their origin in an RAG-expressing
lymphoid progenitor (Figure 3B).
We next evaluated the extent to which lymphoid and myeloid
programs were co-resident in individual cells through develop-
ment. Cells were operationally considered myeloid primed if ex-
pressing two or more of CD33, IL3RA, MPO, CSF1R, CSF2RA,
and CSF3R, lymphoid primed if expressing two or more of
CD7, CD10, and RAG2, or B committed if expressing two or
more of EBF1, PAX5, and CD19. This analysis revealed a transi-
tion from a primarily myeloid progenitor state at CS17, to a pre-
dominantly lymphoid state in CB and adult BM, transiting
through a B-myeloid (GM/B) state at CS20, which was rare or
not present at other (CB and adult BM) developmental stages
(Figure 3C). Qualitatively, the lymphoid program appeared
different in adult BM from CS20 FL, with higher expression of a
core lymphoid program, but less consistent expression of B line-
age-restricted genes.
To determine whether the IL-7R progenitor and proB cells
from different stages of development could be objectively sepa-
rated by their overall pattern of gene expression, we analyzed
the single-cell qPCR data by principal-component analysis
(PCA) (Figure 3D). The proB cell clusters from FL, CB, and adult
BM overlapped, with proB cells from adult BM displaying
the least heterogeneity. However, the IL-7R progenitor compart-
ments from different developmental stages formed distinct
clusters along a developmental axis, with the early CS17 FL pro-
genitor also segregating from later CS20 FL IL-7R progenitors.
Genes contributing most strongly to the signature of the early
FL IL-7R progenitor included the myeloid tyrosine kinase recep-
tor CSF1R (M-CSFR) and LIN28B.
Lymphoid Commitment in hPSC Culture Recapitulates
Human Fetal B Lymphopoiesis
Wespeculated that hPSCsmight be able tomodel the character-
istics of fetal lymphopoiesis. For these studies we used a human
induced PSC (hIPSC) line, MIFF3, and corroborated our findings
using the H1 human embryonic stem cell (hESC) line. An OP9/
MS5 sequential co-culture system was used to differentiate
hPSCs to the B cell lineage (Figure 4A) (Carpenter et al., 2011;
Vodyanik et al., 2005). Co-cultured hematopoietic cells were
analyzed after 10 days of OP9 co-culture (D10) and after further
co-culture in lymphoid conditions on MS5 (approximately D31).
Pro and preB cells were readily produced from MIFF3 hIPSCs
(Figure 4B). Differentiation of H1 hESCs performed similarly to
that seen from MIFF3 hIPSCs (Figure S3A) (Carpenter et al.,
2011). An IL-7R progenitor (CD19CD34+CD45RA+IL-7R+) of
A B
C D
E F
Figure 2. Identification of a CD19–IL-7R+ Progenitor
(A) Fluorescence-activated cell sorting (FACS) analysis of CS17 FL showing CD19IL-7R+ progenitor co-expressing CD34 andCD45RA. Adult BM (right) is shown
for comparison. Cells were gated CD45+LINCD19–. Further gating as indicated. Mean percentage of total CD45+CD34+ cells.
(B) Kinetics of IL-7R progenitor emergence during development as percentage of total CD45+CD34+ cells. Each dot represents one biological sample. Mean with
range. Statistical comparison versus CB control.
(C) B cell potential of IL-7R+KIT+ FL progenitorswas tested by co-culture onMS-5 for 2 weeks. Percentage of CD19+ B cells of total CD45+ cells is shown (left) with
representative FACS analysis (right). CD34+ cells were used as control. Mean ± SD, n = 2–3.
(D) Agarose gel of IGHDJ rearrangements in IL-7R+ FL progenitor. Top: DH7JH recombination assay. Bottom: DH1-6JH recombination assay. Label for lanes 1–6 is
shown to the right. Marker lanes (M). Predicted DH7JH recombination between 100 and 130 bp. Predicted DH1-6JH rearrangements between 110 and 290 bp, n =
1 (van Dongen et al., 2003).
(E) GM and erythroid potential of IL-7R+KIT+ FL progenitor in semi-solid media. Data show distribution of colony types as percentage of plated cells versus CD34+
cells as controls. Mean ± SD, n = 2 per developmental stage.
(F) Myeloid potential of IL-7R+KIT+ FL progenitor in liquid culture (20–40 cells/well). Graph shows percentage of wells expanded to >50 cells (left). Cytospin of
macrophages generated from FL IL-7R+KIT+ progenitor (right). Mean ± SD, n = 3.
See also Figure S2.
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to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1, Developmental Cell (2017), https://doi.org/10.1016/j.devcel.2017.12.005similar phenotype to the IL-7R progenitor observed in FL was
also identifiable at D31 (Figures 4B and S3A). This progenitor
was also seen as early as D10, significantly before the emer-
gence of B cells or the addition of lymphoid cytokines. Popula-
tion-level qPCR gene expression analysis from D31 confirmed
the lymphoid nature of the D31 IL-7R progenitor and proB cells,
and expression of LIN28B confirmed their fetal character (Fig-
ure 4C, sorting strategy Figure S3A) (Yuan et al., 2012). As in
the FL, the IL-7R progenitor gave robust B cell output on MS5
co-culture (>70% of CD45+ cells) and macrophage colonies in
semi-solid medium, but with no erythroid colonies (Figures
S3B and S3C).We tested the clonal macrophage potential of sin-
gle-cell hPSC-derived IL-7R progenitor in liquid culture, showing
a robust cloning frequency equivalent to that from the primitive
CD34+CD45RA controls (13% versus 20%) (Figure S3D).
We next used RNA sequencing (RNA-seq) to globally measure
the similarity between hPSC- and FL-derived B cell hierarchies.
We examined both IL-7R progenitor and proB cell populations,
and used LINCD34+CD38CD45RA cells as more primitive
controls (Doulatov et al., 2012). We controlled for any variation
between individual specimens by analyzing biological replicates
of each population. The data were analyzed by PCA as a mea-
sure of the overall similarity between samples. We first con-
structed a PCA map to compare B lymphopoiesis in adult BM
with FL. As expected, PCA clearly separated the populations
into three distinct clusters based on differentiation stage (PC1,
28.5% explained variance) (Figure 4D). Furthermore, the differ-
entiation hierarchies from adult and fetal samples were also
clearly separable based on developmental origin (PC2, 16.2%
explained variance). Remarkably, interpolating the hPSC
lymphoid hierarchy (hIPSC [MIFF3] as well as hESCs [H1]) onto
this plot revealed that the hPSC clusters closely mapped with
those seen from human FL and clearly separate to those from
adult BM (Figure 4D). This interpolation strategy was used to
mitigate distortion of the PCA by culture-related signatures;
however, a PCA, calculated using primary and hPSC samples,
produced similar results, with hPSCs further separated from
adult BM (Figure S3E). Collectively these global gene expression
profiles support the notion that in vitro hPSC differentiation
closely reflects that seen in FL, with both being distinct from
adult. Since cALL is initiated in fetal tissues, this indicates that
hPSCs provide a developmentally relevant model of early em-
bryonic human B lymphopoiesis in which to model the pre-
leukemic initiation of cALL.
Lastly, we used single-cell qPCR to explore whether the hPSC
system exhibits the transition from myeloid to lymphoid pro-Figure 3. The IL-7R Progenitor Transitions from a Myeloid to a Lympho
(A) Single-cell qPCR analysis of IL-7R+KIT+ progenitor from different developmen
represents a single cell, colored by cycle threshold (CT) value. Only cells expressin
related; 44–60 cells and n = 3 per developmental stage.
(B) Agarose gel of DH7JH rearrangement in myeloid cells derived frommyeloid liqu
lanes (M) 1 kb+ (Invitrogen). Predicted DH7JH recombination band 100–130 bp (v
(C) Co-expression of lineage-associated genes in IL-7R+KIT+ progenitor based on
(B) if expressing two genes representative of that lineage, as defined in Figure 3
labeled GM/L and GM/B, respectively. Only cells expressing GAPDH and IL7R w
(D) PCA from single-cell qPCR data of IL-7R+KIT+ progenitor (triangles) and proB
Each dot represents a single cell. Right graphs show the direction and magnitud
differentially expressed genes, respectively. Thirty-six genes were used for th
confidence for each cellular compartment.gramming seen in the human FL IL-7R progenitor compartment.
The early D10 IL-7R progenitor exhibited a strong and relatively
uniformmyeloid signature similar to the fetal CS17 IL-7R progen-
itor. By D31 there was a mixture of myeloid-, lympho-myeloid-,
and B lineage-primed cells (Figures 4E and S3F). Analysis by
PCA showed that the early D10 hPSC-derived progenitors over-
lapped closely with CS17 FL, whereas D31 IL-7R progenitor
overlapped both the CS17 and CS20 FL progenitors, reflecting
the mix of myeloid- and lympho-myeloid-primed cells seen in
Figure 4E (Figure 4F). The hPSC proB cells clustered away
from the IL-7R progenitor, partially overlapping the territory
occupied by the CS20 FL proB cells and distinct from adult
BM proB cells (Figure 4F).
Thus, the hPSC-derived IL-7R progenitor and proB cells
resemble the FL cells both functionally and transcriptionally,
and the hPSC cultures appear to recapitulate the myeloid to
lympho-myeloid transition seen in the IL-7R progenitor during
embryonic development. As such, this system offers an experi-
mentally tractable system in which to model the pre-leukemic
phase of ALL initiated by ETV6-RUNX1 in early human ontogeny.
An hIPSC Model of ETV6-RUNX1 Shows a Block in
B Lineage Commitment
Since ETV6-RUNX1’s impact is likely dose-dependent, we used
a homologous recombination knockin approach to ensure
appropriate regulation and levels of ETV6-RUNX1. The cDNA en-
coding RUNX1 exons II–VIII was introduced into the native ETV6
locus of MIFF3 hIPSCs at the breakpoint region by CRISPR
Cas9D10A-directed homologous recombination (Figure 5A).
ETV6-RUNX1 is linked to an mVenus reporter by a self-cleaving
2A peptide. hPSC clones were genotyped by Southern blot hy-
bridization and tested for normal karyotype and ongoing expres-
sion of pluripotency markers (Figures S4A–S4E). Importantly,
western blot analysis confirmed expression of the ETV6-
RUNX1 protein at levels equivalent to that seen in the ETV6-
RUNX1-expressing cell line REH (Figure S4F).
ETV6-RUNX1-expressing clones produced either no or low
numbers of immunophenotypically defined CD19+ proB and
preB cells relative to control cultures, although an IL-7R progen-
itor could be detected at numbers similar to that in controls (Fig-
ures 5B and 5C). This suggests that ETV6-RUNX1 affects a
partial block in B cell differentiation at the IL-7R progenitor to
proB cell transition. To directly attribute the cellular and molecu-
lar phenotypes seen in the knockin cells to ETV6-RUNX1
expression, we cloned two further control lines where the
RUNX1 knockin cassette had been removed using TAT-CRE.id Gene Expression Signature during Early Embryonic Development
tal stages; FL CS17 (left), FL CS20 (middle), and adult BM (right). Each column
gGAPDH are shown. Gene sets: red, myeloid; blue, lymphoid; green, B lineage
id culture of CS20 IL-7R+ progenitors (also sorted positive for KIT), n = 1; marker
an Dongen et al., 2003).
single-cell qPCR. Cells are consideredmyeloid (GM), lymphoid (L), or B-primed
A. Co-expression of two or more of each of the GM and L and or B genes are
ere analyzed.
cells (squares) from FL (CS17 [progenitor only] and CS20), CB, and adult BM.
e of eigenvectors contributing to separation for lineage-associated and most
e PCA, n = 2–3 per developmental stage. Ellipses represent region of 90%
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Figure 4. Lymphoid Commitment in hPSC Culture Recapitulates Human Fetal B Lymphopoiesis
(A) hPSC in vitro B cell differentiation protocol. hPSCs are harvested onto a layer of overgrown OP9 and co-cultured for 10 days. After CD34 enrichment, cells
were either analyzed (D10) or co-cultured for an additional 21 days on MS-5 in the presence of lymphoid cytokines as indicated (D31) (Carpenter et al., 2011).
(legend continued on next page)
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any confounding effects of this part of the construct (Strathdee
et al., 2006; Zhu et al., 2015). These reverted clones produced
proB and preB cells at the expected frequency (Figures 5B
and 5C). We tested whether cells expressing ETV6-RUNX1
exhibited any clonal advantage over wild-type by competitive
co-culture of wild-type MIFF3 and ETV6-RUNX1 knockin
CD34+ cells from D10 of culture (Figure 5D). By days 29–31 of
B lineage-differentiating conditions, wild-type CD34CD19+
preB cells dominated (98%, *p < 0.05), whereas the more prim-
itive ETV6-RUNX1+ IL-7R progenitors outcompeted their wild-
type counterparts (83%, *p < 0.05) (Figure 5E). Overall, these
data suggest that ETV6-RUNX1 affects a partial block in early
B cell lineage restriction at the IL-7R progenitor to proB cell tran-
sition, resulting in a relative expansion of the IL-7R progenitor.
ETV6-RUNX1 ‘‘proB’’ Cells Exhibit Multilineage Priming
and Potential
To explore the point in B cell differentiation that ETV6-RUNX1 is
having its first transcriptional impact, we performed global RNA-
seq on the ETV6-RUNX1 B lymphoid hierarchy, including the
small numbers of ETV6-RUNX1 proB cells that escaped the dif-
ferentiation block. Overlaying these data on the PCA calculated
using primary human cells showed that ETV6-RUNX1+ primitive
CD34+CD45RA and IL-7R progenitor compartments clustered
with the IPS-derived cells at the global level. In contrast, the
ETV6-RUNX1-expressing CD19+ ‘‘proB’’ cells clustered with
CS17 and control hPSC-derived IL-7R progenitor, rather than
control hPSC-derived proB cells (Figure 6A, left). We used
gene set enrichment analysis (GSEA) to confirm that the
ETV6-RUNX1+ ‘‘proB’’ cells were indeed more mature than the
ETV6-RUNX1+ IL-7R progenitor, showing marked enrichment
for known proB cell genes (Laurenti et al., 2013) (normalized
enrichment score 2.07, false discovery rate q = 0.00) (Fig-
ure S5A). ProB cells derived from the reverted ETV6-RUNX1–
hPSC lines clustered with their wild-type counterparts,
demonstrating that this shift in programming is attributable to
the presence of ETV6-RUNX1 (Figure 6A, right).
We investigated to what extent genes, known to be altered in
B-ALL, also changed in our IPS ETV6-RUNX1 model. The
erythroid-associated gene EPOR, known to be upregulated in
ETV6-RUNX1+ B-ALL, was significantly increased in the IPS
ETV6-RUNX1 proB cells (Torrano et al., 2011) (Figure 6B). We
found the lymphoid- and B-related genes IL7R, EBF1, and the(B) DifferentiatedMIFF3 hPSCswere analyzed for CD19+ B cells (top) andCD19–IL
CD45+IGM; further gating as indicated. Mean percentages of CD45+ cells, n =
(C) qPCR of D31 hPSCs. CD34+CD45RA, IL-7R+ progenitor, and CD34+CD19+
PAX5), megakaryocytic/erythroid (GATA1), and fetal-specific (LIN28B) genes. Da
(D) PCA of RNA-seq data. Left: PCA based on primary cells only; LINCD34+CD45
n = 2). Right: hPSC-derived cells and the early CS17 FL IL-7R+ progenitor (outlier) w
from D31 (CD34+CD45RA, IL-7R+ progenitor, and proB cells) of differentiation.
show the 90% density function for that cell type.
(E) Single-cell qPCR analysis of IL-7R+ progenitor from D10 and D31 of differentia
cells expressing GAPDH are shown. Genes in red are myeloid, blue are lym
n = 2/population.
(F) PCA calculated from single-cell qPCR data from the human primary cells (Figu
progenitor only) and D31 (IL-7R+ progenitor and proB cells). Each dot represents
cell clusters, 36 genes were used for the PCA, n = 2–3.
See also Figure S3.B cell tumor suppressor PAX5, to be significantly downregulated
in the ETV6-RUNX1+ proB cells, whereas more myeloid genes
(CSF1R, SPI1, and CEBPA), and those expressed in more prim-
itive cells (FLT3 and MPL), were upregulated (Abdelhaleem,
2007; Iijima et al., 2000; Tijchon et al., 2013) (Figure 6B). Target
genes of the B cell transcription factor, STAT5, activation of
which is known to co-operate with haploinsufficiency of PAX5
and EBF1 in initiating ALL (Heltemes-Harris et al., 2011), were
markedly upregulated in ETV6-RUNX1 proB cells, as shown by
GSEA (Figure 6C). These observations indicate that the hIPSC
ETV6-RUNX1+ proB cells share significant molecular similarities
to those seen in cALL. As a first hit in our model, ETV6-RUNX1
undermines B lineage identity of the pre-leukemic proB cells
and facilitates the co-expression of signaling and transcriptional
regulators associated with more primitive and myeloid lineages.
To gain a broader appreciation of how ETV6-RUNX1 affects
B lineage commitment we usedGSEA of the RNA-seq data inter-
rogating HSC-, megakaryocyte/erythroid (MkE)-, myeloid-, and
B cell-associated signatures (Laurenti et al., 2013) (Figure 6D).
The ETV6-RUNX1+ ‘‘proB’’ cells were highly enriched for HSC,
MkE, andmyeloid genes compared with hPSC-derived controls.
Although the early B cell signature was less well developed in
ETV6-RUNX1 ‘‘proB’’ cells than in controls, they nevertheless
displayed components of B cell identity. We analyzed this further
by single-cell qPCR to assess the extent of heterogeneity and
co-expression of lineage-affiliated genes in the ETV6-RUNX1-
expressing ‘‘proB’’ cells. ETV6-RUNX1 ‘‘proB’’ cells had wide-
spread co-expression of a B-myeloid signature, significantly
enhanced relative to that from both MIFF3 and reverted hPSC-
derived proB cells (Figures 6E, S5B, and S5C). This suggests
that expression of ETV6-RUNX1 imposes or maintains multiline-
age gene expression priming characteristic of primitive cells,
which is not fully resolved as the cells initiate B lineage
commitment.
The increased expression of myeloid surface markers promp-
ted us to investigate if the ETV6-RUNX1 ‘‘proB’’ cells could sur-
vive in liquid culture supplemented with myeloid cytokines. We
found a significant increase in small colonies after 2weeks of cul-
ture compared with wild-type proB cells, demonstrating an
increased survival of these pre-leukemic cells (Figure 6F). In
addition, a proportion (8.8%) of the ETV6-RUNX1 ‘‘proB’’
cell clones differentiated into large macrophage-containing col-
onies, demonstrating that ETV6-RUNX1+ ‘‘proB’’ cells exhibit an
unexpected capacity for lineage plasticity (Figures 6G and 6H).-7R+ progenitor (bottom) at D10 (left) andD31 (right). Cells were gated CD45+ or
5–7.
proB cells were analyzed for expression of lymphoid (IL7R, RAG2, EBF1, and
ta are normalized to GAPDH, mean ± SD, n = 2–3.
RA, IL-7R+ progenitor, and proB cells from adult BM (n = 3) and FL (CS21-22,
ere placed on the PCA calculation shown to the left. hPSCs (MIFF3 andH1) are
PCA1 and PCA2 are shown and each dot represents one sample. The ellipses
tion (MIFF3). Each column represents a single cell. Colored by CT value. Only
phoid, and green are B cell genes. A total of 35–58 cells per time point,
re 3D) and differentiated hPSCs (MIFF3 and H1). hPSCs are from D10 (IL-7R+
a single cell (only hPSCs shown). Highlighted ellipses represent primary human
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Figure 5. An hIPSC Model of ETV6-RUNX1
Shows a Block in B Lineage Commitment
(A) Genome engineering strategy. A constitutive
knockin cassette, encoding a splice acceptor (SA),
cDNA for RUNX1 exons II–VIII V5 tagged at the
C terminus, and linked to the mVenus fluorescent
reporter by a self-cleaving furin/T2A peptide is in-
serted by CRISPR-directed homologous recom-
bination toward the 50 end of ETV6 intron V. The
cassette is flanked by LoxP sites and includes a
30 triple stop/poly(A) tail followed by an FLP flox-
able NeoR+ selection cassette.
(B) Control MIFF3 (top panel), ETV6-RUNX1
hPSCs (middle panel) and reverted ETV6-RUNX1
hPSCs (bottom panel) were cultured according to
Figure 4A and analyzed by flow cytometry for
Venus reporter (left), proB (CD34+CD19+) and preB
(CD34CD19+) cells (middle), and IL-7R+ progen-
itor (right). Viable cells were gated as indicated.
(C) Frequencies of IL-7R+ progenitor, proB, and
preB cells in MIFF3 cells compared with ETV6-
RUNX1 iPSCs and reverted ETV6-RUNX1
hPSCs analyzed at D27-31. Percentage of Venus
(MIFF3/reverted clone) or Venus+ (ETV6-RUNX1
hIPSC) CD45+ blood cells. Each dot represents
one replicate. Only samples with 8,000 cells or
more were considered.Mean ± SD. Statistics were
performed using MIFF3 as control group, ns, not
significant.
(D) Schematic drawing of in vitro competitive
assay. Equal numbers of ETV6-RUNX1 and wild-
type MIFF3-derived CD34+ cells from D10 of OP9
co-culture were seeded onto MS5 in B differenti-
ating conditions. The proportions of Venus+ and
Venus preB cell and IL-7R progenitors were
analyzed by FACS at D29-31.
(E) Differentiated MIFF3 and ETV6-RUNX1+
hPSCs, grown in competition, were analyzed for
CD34CD19+ B cells (top) and CD19IL-7R+ pro-
genitor (bottom) at D29–D31. Cells were gated
CD45+; further gating as indicated. FACS plot
of representative sample annotated with mean
percentages values. Summary bar charts show
mean ± SD, *p < 0.05, n = 4.
See also Figure S4.
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by demonstrating IGH DJ recombination in the myeloid cells
(Figure 6I).
These data are consistent with ETV6-RUNX1 functioning as a
first-hit mutation by specifically dysregulating a developmentally
restricted myeloid to lymphoid transition; this partially blocks
B lineage commitment resulting in pre-leukemic ‘‘proB’’ cells
that retain the characteristics of a primitive fetal lympho-myeloid
progenitor.
DISCUSSION
Our study was predicated on the hypothesis that developmental
differences in human fetal B cell progenitors may provide a sus-
ceptibility to pre-leukemic initiation by ETV6-RUNX1. Herein, we
report that: (1) the earliest CD19IL-7R+ lymphoid progenitors in
the human FL transition from amyeloid to lymphoid gene expres-
sion signature during development; (2) these transcriptional
states, unique to early fetal development, can be recapitulated
in vitro by the directed differentiation of hPSCs; and (3) a hPSC
model of ETV6-RUNX1 specifically affects this developmental
transition, resulting in expansion of the CD19IL-7R+ compart-
ment, a partial block in B lineage commitment and the produc-
tion of proB cells with aberrant myeloid gene expression
signatures and potential. Our results are consistent with the
notion that the changes in transcriptional states occurring in he-
matopoietic progenitors during early human B cell ontogeny pro-
vide a developmental susceptibility to pre-leukemic initiation by
ETV6-RUNX1.
Despite extensive efforts to model infant and childhood
B-ALL, including ETV6-RUNX1, in mice (Schindler et al., 2009;
van der Weyden et al., 2011), these have so far provided limited
insight into the earliest stages of pre-leukemic initiation and
failed to faithfully recapitulate the lymphoid disease, highlighting
the need to explore developmentally relevant human model sys-
tems. We have addressed this by exploring the earliest stages of
human fetal B lymphopoiesis, the developmental stage from
which cALL is presumed to initiate. While examining the func-Figure 6. ETV6-RUNX1 ‘‘proB’’ Cells Exhibit Multilineage Priming and P
(A) RNA-seq data from ETV6-RUNX1-expressing iPSCs overlaid (haloed) on the e
derived data (haloed) are shown for comparison (left). PCA also including reverted
one sample. The ellipses show the 90% density function for that cell type. Two d
Reverted clone, n = 2, in one experiment.
(B) Comparison of gene expression in MIFF3/reverted ETV6-RUNX1 (RC) (green)
Bars show mean fragments per kilobase of transcript per million fragments map
(C) Gene set enrichment analysis (GSEA) of STAT5A target gene expression comp
NES, normalized enrichment score. FDR, false discovery rate.
(D) GSEA as in (C). Lineage affiliations of gene sets used are indicated above (La
(E) Single-cell qPCR data of control MIFF3 and ETV6-RUNX1+ proB cells from D3
red aremyeloid, blue are lymphoid, and green are B cell genes. Only cells express
population, n = 2–3.
(F) Survival of MIFF3/reverted ETV6-RUNX1 (RC) (green) and ETV6-RUNX1 Venu
culture supplemented with myeloid cytokines (percentage of wells with R3 cell
experiments.
(G) Myeloid differentiation potential MIFF3/reverted ETV6-RUNX1 (RC) (green) a
grown in liquid culture supplemented with myeloid cytokines (percentage of w
reverted = 6, in two experiments.
(H) Cytospin of macrophages generated from ETV6-RUNX1+ proB cells.
(I) Agarose gel of DH7JH rearrangements in myeloid cells derived from liquid cultu
RUNX1+ CD34+ cells. Marker lanes (M) 1 kb+ (Invitrogen). DH7JH recombination
12 Developmental Cell 44, 1–16, February 5, 2018tional effects of ETV6-RUNX1 in primary human fetal material
is technically infeasible, we hypothesized that hPSCs might pro-
vide a platform in which to model human fetal lymphopoiesis.
Therefore, in parallel, we have characterized the nature of B lym-
phopoiesis emanating from hPSCs in vitro, aiming (1) to under-
stand the extent to which this model system reflects fetal, as
opposed to adult, B lineage hierarchies, thus providing a trac-
table experimental model to analyze themolecular events under-
lying B lineage commitment in utero, and (2) explore how these
developmental processes confer susceptibility to oncogenes
that act in utero, such as ETV6-RUNX1.
Strikingly, the first B cells that emerge during human develop-
ment are distinct from their adult compartments in their exten-
sive expression of IL-7R, allowing us to identify a CD19IL-7R+
lymphoid progenitor. At CS17, where B cells first emerge, the
CD19IL-7R+ progenitor expresses a predominantly myeloid
gene expression program, whereas by CS20, where B cell pro-
duction is more robust, the IL-7R progenitor exhibits a lympho-
myeloid program, which single-cell gene expression analysis
demonstrates as being co-resident within individual cells. This
B-myeloid co-expression occurs even in the presence of B cell
master regulators, notably the transcription factor PAX5. Consis-
tent with this molecular analysis, the CD19IL-7R+ compartment
produced both B and myeloid cells at the population level, and
myeloid cells derived from the IL-7R progenitor harbored IGH
DJ rearrangements, confirming their origins from a RAG+
lymphoid progenitor (Figure 3B). This mix of myeloid and lym-
pho-myeloid programming distinguishes the early fetal IL-7R
compartment from the IL-7R+ progenitors previously reported
in adult and later fetal developmental stages, which have been
characterized as lymphoid progenitors (Roy et al., 2012; Ryan
et al., 1997).
The developmental nature of in vitro hPSC-derived hemato-
poietic progenitors is an area of considerable controversy (Sluk-
vin, 2013). T and, where achieved, B lymphoid output is generally
considered evidence of ‘‘definitive’’ hematopoiesis, but repro-
ducible derivation of engraftable dHSCs from hPSCs has been
elusive, raising the possibility that B lymphopoiesis from hPSCsotential
xisting PCA map calculated from primary samples (Figure 4D). Control hPSC-
ETV6-RUNX1 IPS (pink) (right). PC1 and PC2 are shown; each dot represents
ifferent ETV6-RUNX1 cell lines (no. 2.1 and no. 2.8) used in thre experiments.
and ETV6-RUNX1 hIPSC (purple) proB cells. Each dot represents one sample.
ped (FPKM) value ± SD, n = 4–5.
aring ETV6-RUNX1 hIPSC (red) with control proB cells at D31 of differentiation.
urenti et al., 2013).
1. Each column represents a single cell. Colored by CT value. Genes labeled in
ingGADPH and ETV6-RUNX1 are shown. A total of 37–56 cells investigated per
s (V)+ hIPSC (purple)-derived single proB cells (CD34+CD19+) grown in liquid
s at 14 days). Mean ± SD, n = ETV6-RUNX1 = 4; MIFF3/reverted = 6, in two
nd ETV6-RUNX1 Venus (V)+ (purple)-derived single proB cells (CD34+CD19+)
ells with R20 cells at 14 days). Mean ± SD, n = ETV6-RUNX1 = 4; MIFF3/
re of ETV6-RUNX1 proB cells (clones no. 2.1 and no. 2.8) and primitive ETV6-
predicted band 100–130 bp (van Dongen et al., 2003). See also Figure S5.
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hPSC derivatives with fetal counterparts provides a crucial point
of reference to understand the developmental nature of hPSC-
derived B lymphopoiesis. In vitro differentiation of hPSCs pro-
duces an IL-7R progenitor with similar functional capacity to
that seen in the early FL. Importantly single-cell qPCR analysis
at different time points during in vitro differentiation demon-
strated a transition from myeloid to lymphoid programming
similar to that seen in the fetus, suggesting that the hPSC system
recapitulates this early developmental lineage progression.
Indeed, our comparison of global transcriptional profiles demon-
strates clear transcriptional differences separating fetal and
adult B lymphopoiesis and reveals that the hPSC-derived hierar-
chy shares a remarkable degree of overlap with the develop-
mental signature of FL. Together our data indicate that hPSCs
provide a good model to understand how ETV6-RUNX1 dysre-
gulates early human fetal lymphopoieis.
In this developmental context, ETV6-RUNX1 initiates a partial
differentiation block at the IL-7R progenitor to proB cell transition
(Figures 5B–5E and 6A). In contrast, murine models using viral
overexpression systems have previously shown that ETV6-
RUNX1 blocks B cell differentiation at the proB (Tsuzuki and
Seto, 2013; Tsuzuki et al., 2004) or preB cell (Morrow et al.,
2004) stage. Although in vitro differentiation of hPSCs to the
B lineage can be technically variable, by producing multiple
knockin cell lines that demonstrate similar phenotypes and by
sub-cloning further lines with the RUNX1 knockin cassette
removed, we have controlled for variability in hPSC culture and
differentiation. Importantly, the knockin approach used here
provides a more authentic recapitulation of the timing and level
of ETV6-RUNX1 expression than has been possible by viral
transgenesis (Tsuzuki and Seto, 2013). The partial nature of
this differentiation block is consistent with the identification of
ETV6-RUNX1+ B cells in pre-leukemic CBs (Mori et al., 2002)
and may explain the requirement for recurrent second-hit muta-
tions targeting other lymphoid master regulators such as PAX5.
The precise mechanism by which ETV6-RUNX1 promotes this
differentiation block remains unclear. Due to the limiting cell
numbers available we were unable to characterize the binding
targets and epigenetic changes induced by ETV6-RUNX1, or
explore how the epigenetic state of the fetal IL-7R progenitor
interfaces with ETV6-RUNX1. However, as protocols for assay-
ing chromatin immunoprecipitation and accessibility are further
refined we think that our model will provide a tractable platform
for transcription factor network analysis of relevant cellular
compartments.
As with previous models, expression of ETV6-RUNX1 in
hPSC-derived B lineage progenitors does not result in transfor-
mation to overt leukemia. Consistent with this we have not
seen engraftment of ETV6-RUNX1 progenitors, nor their control
counterparts, upon transplantation into the livers of newborn
NSG mice (data not shown). However, the potency of the
leukemic phenotypes observed needs to be placed in the
context of the low penetrance of ETV6-RUNX1 as an oncogene;
thus, of the 1% of children born harboring this mutation only 1%
progress to leukemia, and those with the pre-leukemia have
no discernible phenotype and only modest pre-leukemic
clonal size (Mori et al., 2002). This notwithstanding, expression
of ETV6-RUNX1 disrupts the myeloid to lymphoid transitionseen in the IL-7R progenitor compartment during development,
impairing B lineage commitment and resulting in a relative
expansion of ETV6-RUNX1+ IL-7R progenitors (Figures 5B–5E)
providing a plausible pre-leukemic impetus.
An important effect of this differentiation block may be to
arrest B lineage progenitors at a stage susceptible to the acqui-
sition of second-hit mutations. RAG recombinase has been
implicated in mediating the majority of second-hit mutations in
ETV6-RUNX1 ALL, and is expressed by both proB cells and
the majority of IL-7R progenitor cells from CS20 (Papaemmanuil
et al., 2014). Importantly, sequencing studies have indicated that
the cell of origin in cALL harbors DJH rearrangements, a feature
we have seen in both the earliest emerging fetal proB and IL-7R
progenitor compartments. These results are consistent with a
model whereby the expanded ETV6-RUNX1+ IL-7R progenitor
sustains a pool of RAG-expressing first-hit cells, although it
is uncertain whether the second-hit mutations occur within
the IL-7R progenitor population itself, or its transcriptionally
abnormal B lineage progeny. Thus, while the IL-7R progenitor
compartment provides a strong candidate cell of origin
for ETV6-RUNX1 pre-leukemia, important questions remain
regarding: (1) in which cellular compartments transformation to
frank leukemia occurs; and (2) how secondary mutations further
disrupt B cell commitment in a genotype and developmental
stage-specific manner. These may be explored by the genera-
tion for further ETV6-RUNX1 expressing hPSC sub-clones that
sequentially model the impact of co-operative second-hit muta-
tions in relevant B lineage compartments.
The ETV6-RUNX1+ ‘‘proB’’ cells that did differentiate exhibited
markedly abnormal geneexpressioncharacterizedbyco-expres-
sion of primitive HSC and myeloid genes. The resultant co-
expression of conflicting signaling and transcriptional pathways
may produce a network level lineage conflict (Banerji et al.,
2013; Enver and Greaves, 1998). Such cells may have differential
responses to niche signals, as well as to altered cytokine environ-
ments produced in response to infection; a proposed accelerator
of leukemic progression (Ford et al., 2009; Greaves, 2006). We
note the very high levels of surface IL-7R expression on fetal
B cells; activatingmutations in the IL-7pathwayare common sec-
ond hits in pediatric ALL, suggesting that this survival pathway
may have relevance in the in utero initiation of B-ALL (Shochat
et al., 2011). IPS reprogramming and myeloid transdifferentiation
of committed B cells have demonstrated the power of the B cell
tumor suppressor PAX5 to both maintain B lineage identity and
extinguish myeloid programming (Hanna et al., 2008; Xie et al.,
2004), yet ETV6-RUNX1 facilitates multilineage priming despite
expression of both EBF1 and PAX5 (although at lower levels
than control), and so in this regard is exerting a profound effect
on lineage regulation. Upregulation of EPOR in the IPS model
also recapitulates what is seen in patients with ETV6-RUNX1+
ALL (Torrano et al., 2011); more broadly we see upregulation of
a battery of myeloid cytokine regulators, the functional relevance
of which is clearly demonstrable by the markedly increased clon-
ing frequency and residual myeloid potential of ETV6-RUNX1+
‘‘proB’’ cells in response to myeloid cytokines (Figures 6F–6G),
a feature reminiscent of the lineage promiscuity characteristic of
cALL. Activation of STAT5 signaling has been seen in ALL attrib-
uted to specific mutations in the STAT5 pathway, and is associ-
ated with adverse prognosis (Heltemes-Harris et al., 2011;Developmental Cell 44, 1–16, February 5, 2018 13
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commonly seen in ETV6-RUNX1 ALL, but interestingly our results
suggest that expression of ETV6-RUNX1 itself leads to upregula-
tion of STAT5 target genes, thereby emphasizing the importance
of STAT5 signaling in ALL in general.
Together our results suggest the hPSC ETV6-RUNX1 model
provides a tractable and developmentally relevant setting
for the examination of how ETV6-RUNX1 initiates pre-leukemia
in utero. The developmentally restricted myeloid to lymphoid
transition seen in the fetal IL-7R progenitor compartment offers
an attractive explanation as to why ETV6-RUNX1 ALL is
overwhelmingly a disease of childhood and why ETV6-RUNX1
B-ALL frequently co-expresses B and myeloid surface markers
(Abdelhaleem, 2007). The transient progenitor-like nature of
this population, coupled with the relatively weak oncogenic
impact of ETV6-RUNX1, may explain the low rate of progression
to ALL and the relatively good response of ETV6-RUNX1 ALL to
chemotherapy. Whether this cellular hierarchy also confers sus-
ceptibility to non-ETV6-RUNX1-associated ALL is an exciting,
but as yet untested possibility. Further analysis of this hPSC-
based model may identify fetal-specific vulnerabilities in ETV6-
RUNX1 ALL, informing new and more specific therapeutic
targets, which could be tested within this tractable platform. In
addition, the model will afford systematic introduction and eval-
uation of the secondary mutations prevalent in ETV6-RUNX1
ALL. Finally the concept that developmentally restricted target
cells are the venues for the initiation of childhood diseases
(Li et al., 2005) suggests that hPSCs could be more broadly
used to model childhood malignancies.STAR+METHODS
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Antibodies
CD45RA FITC (Human primary samples) ThermoFisher #MHCD45RA01v/ MEM-56
CD34-FITC (IPS samples) Biolegend #343604 / 561
CD43 FITC (IPS samples D10) BD #555475 / 1G10
KIT (CD117)-PE (Human primary samples) BD #555714 / YB5.B8
CD19-PE (IPS samples) Biolegend #302254 / HIB19
CD56 PECY5 (LIN) (Human primary samples) BD #555517 / B159
CD3 PECY5 (LIN) (Human primary samples) Biolegend #300310 / HIT3a
CD8a-PECY5 (LIN) (Human primary samples) Biolegend #301010 / RPA-T8
CD235-PECY5 (LIN) (Human primary samples) BD #561776 / GA-R2 (HIR2)
CD45RA PECy7 (IPS samples) Biolegend #304126 / HI100
CD38-PECY7 (Human primary samples) eBioscience #25-0384-42 / HIT3
IGM-APC (IPS samples D31) eBioscience #17-9998-42 / SA-DA4
CD34-APC (Human primary samples) eBioscience #17-0349-42 / 4H11
CD45-A700 Biolegend #304024 / HI30 or #368513 / 2D1
IL7R (CD127)-BV421 BD #562436 / HIL-7R-M21
CD19-BV605 (Human primary samples) BD #562653 / SJ25C1
CD19 APCeF780 (IPS samples) eBioscience #47-0199-42 / HIB19
TRA1-60-PE (IPS) BD #560884 / TRA-1-60
SSEA3-AF647 (IPS) BD #561145 / MC-631
CD14-FITC (B readout) Biolegend #325604 / HCD14
CD34-FITC (B readout) Biolegend #343604 / 561
CD45RA-FITC (B readout) Thermofisher #MHCD45RA01/ MEM-56
CD19-PE (B readout) Biolegend #302254 / HIB19
KIT (CD117)-PE (B readout) BD #555714 / YB5.B8
CD33-PECy7 (B readout) eBioscience #25-0338-42 / WM-53
CD34-PECy7 (B readout) Biolegend #343516 / 581
CD38-PECY7 (B readout) eBioscience #25-0384-42 / HIT3
CD45RA-PECy7 (B readout) Biolegend #304126 / HI100
CD11b-APC (B readout) Biolegend #101211 / M1/70
CD34-APC (B readout) eBioscience #17-0349-42 / 4H11
CD45-A700 (B readout) Biolegend #304024 / HI30
IL7R (CD127)-BV421 (B readout) BD #562436 / HIL-7R-M21
NKP46-BV421 (B readout) Biolegend #331927 / 9E2
CD19-BV605 (B readout) BD #562653 / SJ25C1
CD14-BV605 (B readout) Biolegend #301834 / M5E2
NKP46-BV650 (B readout) Biolegend #331927 / 9E2
TO-PRO 1 (viability) ThermoFisher #T3602
7-Aminoactinomycin D (7-AAD) (viability) Sigma Aldrich, BD #A9400 / #51-68981E
Propidium Iodide (viability) ThermoFisher #P3566
IGG1 kappa - murine myelmoa (Fc-Block) Sigma Aldrich #M9269 / MOPC21
RUNX1 (Western) (1ug/ml) Abcam #ab23980
Histone H3 (Western) (1ug/ml) Abcam #ab1791
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Biological Samples
Human fetal liver Anonymous donation N/A
Cord blood Anonymous
donation /Poietics
N/A / #2C-150A
Adult Bone Marrow Anonymous donation N/A
Chemicals, Peptides, and Recombinant Proteins
h Monocyte- Colony Stimulating Factor (hM-CSF)
Terasaki (some experiments) 25ng/ml
PeProTech #300-25
h Granulocyte- Colony Stimulating Factor (hG-CSF)
Terasaki 50ng/ml
PeProTech #300-23
h Granulocyte Monocyte- Colony Stimulating Factor
(hGM-CSF) Terasaki (only some experiments) 25-50ng/ml
PeProTech #300-03
h interleukin 3 (hIL-3) Terasaki 50ng/ml, IPS diff 10ng/ml PeProTech #200-03
h FLT3 Ligand (hFLT3L) Terasaki/B/IPS diff 50ng/ml PeProTech #300-19
h Stem Cell Factor (hSCF) Terasaki/B/IPS diff 50ng/ml PeProTech #300-07
h Thrombopoietin (hTPO) Terasaki/B 50ng/ml PeProTech #300-18
h Thymic stromal lymphopoietin (hTSLP) B (only some
experiments) 10ng/ml
PeProTech #300-62
h interleukin 7 (hIL7), IPS diff 20ng/ml PeProTech #200-07
mTeSR1 Stem Cell Technologies #85850
Matrigel (IPS) Corning #354277
StemFitAK (IPS) Ajinomoto N/A
FCS batched defined (IPS differentiation) HyClone/Thermofisher #SH30070.03 / #26140079
TAT-Cre Millipore #SCR508
Critical Commercial Assays
MethoCult H4435 Stem Cell Technologies #04435
Cell Direct one-step qRT-PCR Kit ThermoFisher #11753100
48.48 Dynamic Array IFC for Gene Expression Fluidigm #BMK-M-48.48
SMARTer Ultra Low input RNA Kit for Seq_v3 Clontech #634851
Nextera XT DNA Sample Preparation Kit Illumina #FC-131-1096
Nextera XT Index Kit Illumina #FC-131-1002
NextSeq 500/550 High Output v2 kit (150 cycles) Illumina #FC-404-2002
Deposited Data
RNA seq data set This paper ArrayExpress: E-MTAB-6382
Experimental Models: Cell Lines
MIFF3 (RRID:CVCL_1E70) University of Sheffield http://hpscreg.eu/cell-line/UOSi001-B
H1 WiCell http://hpscreg.eu/cell-line/WAe001-A
Oligonucleotides
Oligonucleotides, see Table S1 IDT /Sigma/ ThermoFisher N/A
Software and Algorithms
PRINSEQ-lite v0.20.4 (Schmieder and
Edwards, 2011)
http://prinseq.sourceforge.net/
manual.html
TopHat2 v2.0.11 (Kim et al., 2013) http://cole-trapnell-lab.github.io/
cufflinks/tools/
Cufflinks v2.2.0 (Trapnell et al., 2010) http://cole-trapnell-lab.github.io/
cufflinks/tools/
Gene Set Enrichment Analysis (GSEA) Broad Institute http://software.broadinstitute.org/
gsea/index.jsp
Prism GraphPad https://www.graphpad.com/scientific-
software/prism/
Flowjo N/A https://www.flowjo.com
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Tariq
Enver (t.enver@ucl.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Cells
Human FLs were donated from elective terminations of pregnancy after informed consent with the approval of the ethical review
board at Lund University and permission from the Swedish National Board of Health and Welfare or was provided by the Joint
MRC/Wellcome Trust (grant # 099175/Z/12/Z) Human Developmental Biology Resource (www.hdbr.org). Fetuses were staged ac-
cording to Carnegie Staging (CS) and were all from first trimester of pregnancy (developmental stages CS17-8pcw; gender not es-
tablished). Single cell suspension of the fetal liver was obtained through mechanical disruption. Human cord blood (CB) and adult
bonemarrow (BM) (healthy volunteers) were donated with the approval of the ethical review board at Lund University. CBwas diluted
in heparin immediately after delivery. Mononuclear cells from CB and BMwere isolated using lympho-prep tubes from Medinor, AB.
CB was also bought from Poietics. CB and BM samples are collected anonymously and information regarding age and gender is
therefore not provided.
Pluripotent stem cells used were; mRNA induced foreskin fibroblast 3 (MIFF3) hIPS cells (University of Sheffield, http://hpscreg.eu/
cell-line/UOSi001-B) and H1 ES cells (WiCell, European hESC registry (http://hpscreg.eu/cell-line/WAe001-A)). The Steering
Committee for the UK Stem Cell approved all work on human ES cells.
METHOD DETAILS
Staining for Flow Cytometry and Cell Sorting
Single cell suspensions were blocked with Fc receptor binding myeloma antibodies and then stained with specific monoclonal
antibodies listed in Key Resources Table (human primary samples and IPS samples). Before analysis and cell sorting the sample
was dissolved in viability dye (Key Resources Table). For cell sorting samples were sometimes enriched with CD34 isolation beads
(Miltenyibiotec) before staining was performed.
Progenitors were identified according to the following surface markers; (LIN-)CD34+CD45RA-: (LIN-)CD19-CD34+(CD38-)
CD45RA-(KIT+), IL7R+(KIT+) progenitor: (LIN-)CD19-CD34+(CD38+)CD45RA+IL7R+(KIT+); ProB; (LIN-)CD34+CD19+; PreB;
CD34-CD19+ or CD34-CD19+IGM-;CD34+: (LIN-)CD19-CD34+. Somemarkers were not used on IPS cells; KIT, CD38 and the lineage
markers (LIN); CD3, CD8a, CD235a, CD56; CD38 surface expression was affected by culture conditions, as previously reported (Dor-
rell et al., 2000), and surface KIT was affected by the addition of exogenous KIT ligand. Samples were analyzed or sorted on an LSR II,
FortessaX20, BD ARIA IIu or BD FACSAria III (all from BD Biosciences) and analysis were performed using the FlowJo software.
Quantitative Gene Expression Analysis
Cells were directly sorted (single cells or 25 cells/population) into 4 ml of lysis buffer (65mM of dNTP mix (TaKaRa), 0.4% of NP40
(Sigma), 2.4mM DTT (Invitrogen), 0.5U/mL RNAseOUT (Invitrogen) in nuclease-free water). cDNA synthesis and target specific
pre-amplification was done using Cell Direct one-step qRT-PCR kit (Life Technologies). Pre-amplification mastermix was added
to each well; 6,25mL of 2X Reaction Buffer, 1ml of SuperScript III RT/Platinum Taqmix and 1.5ml of TaqMan assay mix. TaqMan assay
mix was prepared bymixing equal volume of all target specific primers (see Table S1) (ThermoFisher). No-RT controls were prepared
with Taq Polymerase (Invitrogen) and no SuperScript III RT enzyme was included. The PCR conditions were: 60 min at 50C, 2 min at
95C and 22 cycles (25 cycles for single cells) of 15 sec at 95C and 4 min at 60C. Pre-amplified product was diluted 1 to 5 and
loaded onto a 48.48 chip together with Taqman universal MasterMix (Life Technologies) and the Taqman assays listed in
Table S1 with the appropriate loading reagents according to manufacturer’s instructions (BioMark 48.48 Dynamic array platform
(Fluidigm)).
In some single cell sorts, index sorting was used and populations separated based on the index analysis. Single cell data are dis-
played as CT values (not normalized). Cells not expressing GAPDH were not considered further and in the analysis of ETV6-RUNX1
IPS cells, only cells expressing ETV6-RUNX1 and GAPDH were considered. Co-expression of lineage-associated genes were
counted according to the following rules: a cell is considered myeloid (GM) if expressing 2 of the myeloid genes, listed in red in Fig-
ure 3, lymphoid (L) if 2 of the genes listed in blue and B primed if expressing 2 of the genes listed in green respectively. Co-expression
of GM and L and or B genes are labeled GM/L and GM/B respectively. Only cells expressing IL7Rwere considered in the count of the
IL7R progenitor and only cells expressing CD19 considered in the count of proB cells.
PCA analysis was performed on the single cell qPCR data. Genes for which the CT value was larger than 30 in all cells were dis-
carded. All remaining CT values larger than 30 were truncated to 30. The scores were then inverted using the formula 30 –Ct. TaqMan
assays used in the PCA analysis are shown in the Table S1.Developmental Cell 44, 1–16.e1–e7, February 5, 2018 e3
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hPSCs were lysed in Trizol (Invitrogen), RNA prepared by phenol extraction and isopropanol precipitation, treated with DNaseI
(Promega) and cDNA produced from 1mg RNA by random primed SuperScript III (Invitrogen). Quantitative PCR was performed
with SYBR Green (Applied Biosystems) using the primers for OCT3/4 and NANOG (see Table S1) and normalized to b-ACTIN.
In Vitro Cultures
Stroma Co-cultures
To evaluate B lymphoid potential, indicated populations were plated on MS5 stroma. Media (a-MEM (Gibco), with 1% Penicillin/
Streptomycin (HyClone), 1% L-glutamine (2mM, Gibco), 1% 2-Mercaptoethanol (0.1mM, Sigma-Aldrich) and 10% Fetal Bovine
serum (FBS, HyClone) supplemented with cytokines) were changed weekly. Cytokines added are listed in Key Resources Table
(B) (hFLT3L, hSCF, hTPO, hTSLP (only some experiments)).. After 2 weeks cells were picked and stained according to antibodies
listed in Key Resources Table B readout. Clones were regarded as B cells if they had a CD19+ phenotype.
Methocult
Indicated cell populations were plated in complete methylcellulose (MethoCult H4435, Stem CellTechnologies) and colonies scored
at day 12-14. Some colonies could be picked and pooled and morphology evaluated on May-Gr€unwald (VWR International) and
Giemsa (VWR International) stained cytospin slides.
Terasaki
Bulk sorted populations were plated as single cells or at a density of 20-40 cells/well in IMDM (HyClone) supplemented with 1%Peni-
cillin/Streptomycin, 1% L-glutamine (2mM) and 20% FBS supplemented with cytokines according to Key Resources Table Terasaki.
(hG-CSF, hIL-3, hFLT3L, hSCF, hTPO and in some experiments hM-CSF and hGM-CSF), Cultures were scored after 12-14 days of
culture. Wells with cells were picked, pooled and morphology evaluated on May-Gr€unwald (Merck) and Giemsa (Merck) stained
cytospin slides.
DJ Rearrangement
The IL7R progenitor (not purified on KIT) and control populations were sorted directly into KAPA Express DNA extraction Kit buffer
(KAPABiosystems) andDNA extracted according tomanufacture’s recommendation. RT-PCRwas performedmixing DNAwithMax-
ima SYBR Green (ThermoFisher) and the primers listed in Table S1 (van Dongen et al., 2003). Two reactions were performed – one
with DH1-6 and the JH consensus primers and one with DH7 and the JH consensus primer, the latter also rise gives to non-specific
‘‘germline’’ bands, but where positive produces bands in the region of 100-130bp. Samples were run with the following program:
15 min hold at 95C followed by 50 cycles of 30 sec at 95C, 30 sec at 60C and 45 sec at 72C and ending with one cycle of 15
sec at 95C, 20 sec at 60C and 15 sec at 95C. The PCR product was run on a gel (2% Agarose, ethidium bromide) with TBE buffer
(ThermoScientific). Genomic DNA from cells derived from myeloid culture was prepared either directly from Terasaki media into
KAPA express DNA extraction buffer, or from stained cytospin slides by overnight demounting in xylene and direct washing in lysis
buffer (NaCl 100mM, Tris-HCl pH 7.5 50mM, EDTA 10mM, SDS 0.5%, Proteinase K 0.8mg/ml). The gDNA was then subjected to a
further purification step using 1:1 phenol:chloroform (Invitrogen), ethanol precipitated in the presence of 10mg glycogen carrier
(Roche) and amplified as above.
Maintenance of hPSCs
MIFF3 IPS and H1 ES cells were cultured on matrigel-coated (Corning) 6 well plates in either mTeSR1 (Stem Cell Technologies) or
StemFitAK (Ajinomoto Co., Inc, Tokyo, Japan) (See Key Resources Table). Cultures were passaged every 4-7 days using gentle
dissociation reagent (SCT) according to manufacturer’s instructions in the presence of Y27632 rock inhibitor (Miltenyi).
In Vitro B Cell Differentiation of hPSCs
In vitro B cell differentiation was performed as previously described (Carpenter et al., 2011; Vodyanik et al., 2005). OP9 stroma (kind
gift from I Slukvin) were overgrown for 8-12 days on gelatinized 10cm plates in OP9 maintenance media (OP9-M: aMEM (Invitrogen),
20% batch tested defined FCS (Hyclone), 100mM monothioglycerol (Sigma), 1x penicillin/streptomycin (Invitrogen)), with a 5ml half
media exchange conducted on day 4. Large colonies of hPSCs were detached by incubation with 1mg/ml collagenase IV (Invitrogen)
diluted in DMEM/F12 (Invitrogen) for 10-90 minutes. 1.5-2x106 hPSCs were seeded per 10cm dish in 10ml of OP9-D media (OP9-D:
aMEM (Invitrogen), 10% defined FCS (Hyclone), 100mM monothioglycerol, 1x penicillin/streptomycin). A complete media change
was conducted on day 1, half media changes were conducted on days 4, 6 and 8 with CD34+ cells harvested on day 10.
At day 10 media was removed and the OP9 matrix was digested with 7ml fresh collagenase IV 1mg/ml in DMEM/F12 at 37C and
7ml fresh 0.05% trypsin (Invitrogen)/0.5mM EDTA (Sigma) at 37C. After 7 minutes the reaction was quenched with 7ml OP9-D
media. Once triturated the cells were strained through a 40mm nylon filter (BD Falcon). After centrifugation the cellular pellet was
re-suspended and enriched using CD34+ MACS beads (Miltenyi) according to manufacturer’s instructions. Following enrichment
the cells were re-suspended in 0.5-1ml OP9-D media, counted and seeded onto MS5 stroma.
MS5weremaintained in T75 flasks inMS5maintenancemedia (MS5-M: aMEM, 10%batch-tested defined FCS (Hyclone), 1x peni-
cillin/streptomycin). 2x105 MS5 cells are seeded in MS5-M media onto 6 well plates 1-2 days prior to use for differentiation.
12.5-50x104 CD34 enriched cells were added to each well in 2ml OP9-D media supplemented with hIL3 10ng/ml, hIL7 20ng/ml,
hFLT3L 50ng/ml, hSCF 50ng/ml (See Key Resources Table). 2ml of the above media (excluding IL3) was added at day 7. A furthere4 Developmental Cell 44, 1–16.e1–e7, February 5, 2018
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numbers of wild type MIFF3 and ETV6-RUNX1 CD34+ cells from day 10 of OP9 co-culture (determined via manual counting after
magnetic bead enrichment or by FACS sorting) were seeded together onto MS5 stroma. Cells were cultured as per the B cell differ-
entiation protocol and analyzed at day 29-31.
Genome Engineering
A homologous recombination vector targeting ETV6 intron V was constructed by BAC recombineering (RP11_418C2 Source Biosci-
ences). BAC-containing DH10B E. coli were grown overnight in 1.4ml of LB/chloramphenicol (10mg/ml). On day 2 an outgrowth of this
culture was made recombineering proficient by electroporation with the pSC101-BAD-gbaA-tet plasmid (recombineering plasmids
provided by Francis Stewart, University of Dresden). Cells were recovered at 30C in 1ml SOC for 2 hours without selection and after
recovery 100ml of the culture was inoculated into a new tube containing 900ml LB chloramphenicol (10 mg/ml) and tetracycline
(4 mg/ml) and incubated at 30C for 20 hours.
The homology arms for the ETV6 targeting vector were subcloned from the BAC by gap-repair. XmaI linearized p15a-DTA-AmpR
backbone plasmid was amplified by Phusion high-fidelity PCR (NEB) using PAGE-purified primers designed with 50bp homology
arms aligned for gap-repair (Primers; See Table S1) followed by DpnI digestion of plasmid template. Following arabinose induction
the E. coli were electroporated with 400ng of cleaned ETV6-specific p15a-DTA-AmpR PCR product. DNA and arabinose negative
controls were also included. The cells were recovered in SOC for 2 hours at 30C then overnight cultures in 1.4ml LB tetracycline
(4mg/ml) and ampicillin (50mg/ml) at 30C. The following day the E. coli were arabinose induced and electroporated with 200ng of
a column-purified PCR product of the rpsL-GentaR positive/negative selection cassette containing 50bp homology arms targeting
the cleavage point of ETV6 CRISPR gRNA (Primers; See Table S1). The cells were recovered in SOC for 2 hours at 30C then cultured
overnight in 1.4ml LB with tetracycline (4mg/ml), ampicillin (50mg/ml) and gentamicin (4mg/ml).
The following day the rpsL/GentaR positive negative selection cassette was replaced with the RUNX1 knock in cassette. The
cassette was designed in silico and commercially synthesized as in two fragments (GeneArt). These were released by XhoI SbfI
double digest and ligated into a pR6K-AmpR plasmid backbone in pir116+ E coli to prevent background transformation during re-
combineering. The knock in cassette flanked by 50bp homology arms targeting the knock in site was released from a pR6K plasmid
backbone by AscINotI double digest. Following arabinose induction the E. coli were electroporated with 600ng of linearized knock in
construct. DNA and arabinose negative controls were also included. The cells were recovered in SOC for 1 hour at 37C then cultured
overnight in 1.4ml LB with ampicillin (50mg/ml) and kanamycin (5mg/ml) at 37C. Plasmid DNA was extracted from the cultures and
retransformed into chemically competent E. coli, plated on Kan/Amp agar and clones verified by restriction digest and sequencing
across all recombineering junctions and the knock in cassette.
Nucleofection and Selection of hPSCs
MIFF3 hPSCs were harvested as single cells using gentle dissociation reagent following 2 hours pre-incubation with rock inhibitor.
2x106 hPSCs were transfected with 2ug XhoI linearized RUNX1 knock-in construct and 4ug each of Cas9D10A (a gift from George
Church (Addgene plasmid #41816), modified to include a 5’NLS, kindly provided by Dr Elspeth Payne, UCL Cancer Institute) and a
single custom ETV6 guide RNA (pBS-ETV6gRNA: target GGCAATTGGAGGCTTCTGCT) using human stem cell nucleofector kit 2 us-
ing programme B016, Nucleofector IIA (Lonza). Cells were recovered into 10ml mTeSR1/Y27632 on a 10cm matrigel-coated plate.
Media was changed daily and at 48 hours 50mg/ml G418 selection was commenced. At day 8-10 single colonies were picked under
microscopic guidance into a 96well plate.When confluent cloneswere replica plated: one plate was frozen at -80C in 90%knockout
serum replacement (Invitrogen)/10% DMSO (Sigma) supplemented with Y27632; the other was lysed for screening by southern blot
at 65C overnight in 50ml cell lysis buffer (NaCl 100mM, Tris-HCl pH 7.5 50mM, EDTA 10mM, SDS 0.5%, Proteinase K 0.8mg/ml).
Screening by Southern Blot Hybridization
96 well plates of cell lysates underwent DNA precipitation by the addition of 50ml isopropanol. The plate was vortexed gently and
incubated at room temperature for 30mins and DNA pelleted by centrifugation at 2,000g for 20mins. After 3 washes in 70% ethanol
and drying for 20mins at room temperature 30ml KpnI-HF digest mix was added (1x NEB CutSmart buffer, 0.2mg/ml BSA, 1mM
spermidine, 20mg/ml RNaseA, 10U/30ml KpnI-HF) and the DNA digested overnight at 37C. The followingmorning 5ml KpnI-HF digest
mix was added (10U/5ml). After 4 hours of further digestion 3ml of 10x loading buffer is added and 2x 96 well plates run on a 200well
0.8% agarose gel in TAE at 100V for 2-3 hours alongside a lHindIII ladder (NEB). The gel was briefly photographed in a UV trans-
illuminator. The gel was depurinated in 250mM HCl for 10mins, denatured in 2x 15min 0.5M NaOH/1.5M NaCl, neutralized in
1.5M NaCl/TrisHCl 0.5M pH7.5 and equilibrated in 20xSSC for 10mins. The DNA was transferred overnight by capillary transfer
onto a positively charged nylon membrane (Roche). The following morning the nylon membrane was UV cross-linked (120mJ
Stratalinker) and the gel stained with ethidium bromide and visualized to confirm complete transfer of DNA.
The nylon membrane was pre-hybridised at 42C in DIG easyhyb buffer for 60mins (Roche). An external Southern probe (SP2) was
produced using HotStar Taq polymerase (Qiagen) from 500pg ETV6 BAC template (Primers see Table S1). Conditions: 95C 15min,
94C 30s, 56C 30s, 72C 2min, repeat 35 cycles, 72C 10min. 100ng of cleaned SP2 PCR product was labeled with 32P-dATP using
random primed Klenow fragment (Agilent). A lHindIII probe was labeled in the same way and the labeled DNA was column purified
(GE). The probesweremelted for 5min at 95Cbefore hybridizing overnight at 42C. The next day themembranewaswashed twice inDevelopmental Cell 44, 1–16.e1–e7, February 5, 2018 e5
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Knockin hPSC Colony Expansion and Checking
Candidate knock in clones were identified from screening Southern blot and thawed onto HS27 human feeder stroma grown on a
matrigel coated 24 well plate in mTeSR1 supplemented with Y27632. hPSC colonies were passaged onto matrigel coated 6 well
plates, stocks frozen and DNA prepared for confirmatory southern blot including internal Neo probing of BamHI digested genomic
DNA (Primers see Table S1).
Immunostaining
hPSC colonies were fixed in 4% paraformaldehyde and permeabilized for 2 hours (PBS w/o Ca/Mg, 1% BSA, 3%FCS, 0.1%
TritonX100) before primary staining overnight with OCT3/4 (SantaCruz 1:200; Secondary stain Cy5 anti-Rabbit IgG 1:1000
Jackson Labs).
Karyotyping
Confirmation of normal karyotype by G banding was kindly performed by Duncan Baker (Sheffield Diagnostic Genetics Service) and
Dr Christian Unger (Centre for Stem Cell Biology, University of Sheffield).
Western Blot
Sorted CD45+Venus+ hIPSC-derived cells or cultured REH (cell line carrying ETV6-RUNX1 fusion) were washed in PBS, pelleted, re-
suspended in cold RIPA buffer (50mM Tris pH8.0, 150mM NaCl, 1% Igepal CA-630, 0.5% Na-deoxycholate, 0.1% SDS) containing
protease inhibitors (cOmplete Mini Protease Inhibitor Cocktail, Roche 11836153001) and incubated on ice for 10 minutes. Lysates
were centrifuged at 20,000g for 10 minutes to pellet the insoluble fraction, supernatants were removed and pellets washed 1x in
RIPA. Pellets were resuspended in RIPA and sonicated in a Bioruptor Pico (Diagenode) for 5 x 30seconds. Samples were subjected
to PAGE and western blotting. ETV6-RUNX1 was detected with an antibody against RUNX1 (Abcam, ab23980, 1ug/ml). Histone H3
was used as a loading control (Abcam ab1791, 1ug/ml). Cell lines NALM6 (N6) and MIFF3 were used as negative controls.
Removal of the RUNX1 Cassette by Cre Recombinase
10 000 hPSCs from ETV6-RUNX1 knock in clone #2.8 were seeded into a matrigel coated 12 well plate in StemFitAK media. The
following day the cells were incubated for 3 hours in 500ml StemFitAK media containing 5mM TAT-Cre (Millipore). hPSCs were
passaged after 48 hours as single cells and plated at limiting dilution. Emerging colonies were picked under microscopic guidance
into 96 well plates and processed as above for screening by Southern blot hybridization (KpnI-HF digest, Neo probe). By designing
the reverted clones to continue to harbor the NeoR selection cassette provided a KI specific Southern probe that can be used to
screen for Cre reverted cells, giving us confidence that these control lines are not sub-clones of contaminating wild type cells.
Furthermore, the ongoing presence of the NeoR cassette allows us to maintain the knock in hPSCs and their reverted clones in
G418 selection, reducing the risk of background contamination by WT hPSCs.
RNA-Seq
22-400 cells were directly sorted into 800ml Trizol and frozen at -80C. RNA was extracted in the aqueous phase after addition of
160ul chloroform, precipitated with an equal volume of isopropanol supplemented with 20mg linear polyacrylamide and washed
once in fresh 80% ethanol. The RNA pellet was re-suspended in 3ml water at 50C for 10 minutes and then kept on ice. 0.5-1ml of
RNA was quantitated using an Agilent Bioanalyser RNA 6,000 pico chip. 100pg (or 1ml of stock if unquantifiable) of RNA used for first
strand synthesis using SMARTER v3 (Clontech) before 16 cycles of amplification according to manufacturer’s instructions. cDNA
was purified on Agencourt AMPureXP magnetic beads, washed twice with fresh 80% ethanol and eluted in 17ml elution buffer.
1ml cDNAwas checked and quantified on an Agilent Bioanalyser high sensitivity DNA chip. Sequencing libraries were produced using
Illumina Nextera XT tagmentation according tomanufacturer’s instructions except using 150pg input cDNA, 5mins tagmentation and
amplification 12 cycles using Illumina XT 24 index primer kit. Libraries were cleaned using an equal volume (50ml) Agencourt
AMPureXPmagnetic beads and re-suspended in 20ml elution buffer. Libraries were checked and quantified on an Agilent Bioanalyser
high sensitivity DNA chip (size range 150-2000bp) and by Qubit dsDNA BR (Molecular Probes). Libraries were pooled to a normalized
concentration of 1.5nM and sequenced on an Illumina NextSeq 500 using 150bp paired end kit as per manufacturer’s instructions.
See also Key Resources Table.
Bioinformatics
Raw reads were initially processed with PRINSEQ-lite v0.20.4 (Schmieder and Edwards, 2011) to trim low-quality reads. They were
further aligned with TopHat2 v2.0.11 (Kim et al., 2013) on the GRCh37 human assembly and FPKM values for protein-coding genes
were calculated with Cufflinks v2.2.0 (Trapnell et al., 2010) using uniquely mapping reads only. Geneswith an FPKM< 5 in every sam-
ple were filtered out. The remaining ones were log-transformed using the formula log2 (FPKM+1). Finally, expression values were
normalised upon quantiles (Bolstad et al., 2003) prior to the PCA analysis. When building the PCA map based on the expression
in primary samples only (FL CS17, FL CS21-22 and Adult BM), the FL CS17 IL7R+ Progenitor sample was detected as a clear outlier.e6 Developmental Cell 44, 1–16.e1–e7, February 5, 2018
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to B Acute Lymphoblastic Leukemia-Associated ETV6-RUNX1, Developmental Cell (2017), https://doi.org/10.1016/j.devcel.2017.12.005A new map based on all other primary cells was used instead and the FL CS17 IL7R+ Progenitor sample was projected on the new
map. When building the PCA map based on the expression of all wild-type samples (hPSC D31 and the aforementioned primary
samples), the FL CS17 IL7R+ Progenitor sample rested on the correct region of the PCA map (Figure S3E). Gene Set Enrichment
Analysis (GSEA) was performed with permutation type=gene set and the gene sets used were obtained from Laurenti et al. (Laurenti
et al., 2013; Mootha et al., 2003; Subramanian et al., 2005). Ellipses on the PCAs were calculated using ggplot stat_ellipse
(http://ggplot2.tidyverse.org/reference/stat_ellipse.html) assuming a multivariate t-distribution and a confidence level of 0.9.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are shown asmean valueswith standard deviation (SD) if not stated otherwise. Statistics was performed using a non-parametric
Mann-Whitney test or Kruskal-Wallis/Dunns test for multiple comparisons. In Figure 2B, CB was used as control group for the
statistical comparisons made and in Figure 5C MIFF3 was used as control group.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNASeq data reported in this paper is ArrayExpress: E-MTAB-6382.Developmental Cell 44, 1–16.e1–e7, February 5, 2018 e7
